10-Q: Inhibrx Biosciences Reports Q3 2026 Progress, Clinical Milestones

Inhibrx Biosciences, Inc. (INBX) filed its Q3 2026 Form 10-Q, detailing advancements in its oncology pipeline, including positive interim data for ozekibart and ordastobart, alongside financial updates and forward-looking statements.

Summary

• Inhibrx Biosciences, Inc. reported its financial and operational results for the quarter ended September 30, 2026.
• The company continues to advance its clinical-stage pipeline, focusing on oncology therapeutics ozekibart (INBRX-109) and ordastobart (INBRX-106).
• Significant progress was noted in clinical trials, including interim data for ozekibart in colorectal cancer and Ewing sarcoma, and Phase 2 results for ordastobart in head and neck squamous cell carcinoma.
• The company received a $2.0 million upfront payment from Pfizer for a non-exclusive license related to 4-1BB binding single domain antibodies.
• As of September 30, 2026, Inhibrx had $199.5 million in cash and cash equivalents, with a reported accumulated deficit of $355.0 million.
• The company believes its current cash position is sufficient to fund operations for at least the next 12 months.
• Interest expense increased significantly due to expanded debt financing, totaling $8.8 million for the quarter and $18.0 million year-to-date.
• The company is preparing for the potential commercialization of ozekibart, pending regulatory approval.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as cautiously optimistic, with significant clinical trial progress and regulatory milestones achieved, balanced by substantial ongoing R&D expenses and a reliance on future financing.

Positives

• Ozekibart demonstrated a 20% Objective Response Rate (ORR) in a Phase 1/2 study for colorectal cancer, significantly higher than historical standard of care (1-6%).
• Ozekibart achieved a 64.5% ORR in advanced/metastatic Ewing sarcoma, with responses ongoing in eight patients, one for over two years.
• Ozekibart met its primary endpoint in a registrational trial for chondrosarcoma, showing a 52% reduction in the risk of progression or death (HR 0.479) and more than doubling median PFS.
• The Biologics License Application (BLA) for ozekibart in conventional chondrosarcoma was accepted for filing by the FDA in June 2026.
• Ordastobart (INBRX-106) in combination with pembrolizumab showed a confirmed ORR of 48.3% in first-line metastatic head and neck squamous cell carcinoma (HNSCC), compared to 26.5% for pembrolizumab alone.
• The combination of ordastobart and pembrolizumab demonstrated a median PFS of 9.6 months versus 4.9 months for pembrolizumab alone in HNSCC.
• Efficacy for ordastobart and pembrolizumab was particularly pronounced in HPV+ HNSCC patients, with an 80.0% cORR for the combination.
• The company received a $2.0 million upfront payment from Pfizer for a license agreement.

Negatives

• The company reported a net loss of $38.7 million for the three months ended September 30, 2026, and $108.8 million for the nine months ended September 30, 2026.
• Total operating expenses for the three months ended September 30, 2026 were $33.7 million, with research and development expenses at $26.0 million.
• Interest expense increased by 175% to $8.8 million for the three months ended September 30, 2026, and by 99% to $18.0 million for the nine months ended September 30, 2026, due to increased debt.
• The company has an accumulated deficit of $355.0 million as of September 30, 2026.
• The company's BLA for ozekibart faces potential hurdles, as contract manufacturers received Form 483 observations from the FDA during pre-approval inspections.
• The company expects to continue incurring significant losses for the foreseeable future.
• The company's cash and cash equivalents decreased from $124.2 million at December 31, 2025, to $199.5 million at September 30, 2026, but the net cash used in operating activities was $102.5 million for the nine months ended September 30, 2026.
• The company is still an emerging growth company and a smaller reporting company, indicating a lack of established profitability and market capitalization.

Risks

• The company depends heavily on the success of its therapeutic candidates, which are in various stages of development and may fail or suffer delays.
• There is no assurance that the BLA for ozekibart will be approved by the FDA, or that additional trials or data will not be required.
• Clinical and nonclinical development is expensive, takes many years, and its outcome is uncertain; candidates can fail at any stage.
• Delays in clinical trials can occur due to various factors, including regulatory disagreements, patient recruitment issues, and manufacturing problems.
• The company relies on third-party contract manufacturers, whose failure to comply with regulations or meet quality standards could impact development and approval.
• The company has never marketed, sold, or distributed a pharmaceutical product and faces significant challenges in building sales, marketing, and distribution capabilities.
• The company may encounter unexpected limitations in reimbursement or market acceptance for its therapeutic candidates if approved.
• The company's reliance on third-party manufacturers exposes it to risks such as breaches of agreements, quality control failures, and intellectual property misappropriation.

Future Outlook

The company believes its current cash and cash equivalents are sufficient to fund operations for at least the next 12 months. Future funding is expected through equity offerings, debt financings, or strategic collaborations. R&D expenses are expected to increase as development progresses. The company is preparing for potential commercialization of ozekibart, which will incur significant pre-commercialization and, if approved, commercialization expenses.

Management Comments

• The company believes that its existing cash and cash equivalents will be sufficient to fund the Company's operations for at least 12 months from the date these consolidated financial statements are issued.
• We expect that research and development expense will continue to increase over the next several years as we continue development of our therapeutic candidates currently in clinical stage development and support our preclinical programs.
• We will need substantial additional capital in the future to support these efforts.
• We expect to continue to incur net losses for the foreseeable future until, if ever, we have an approved product and can successfully commercialize it.

Industry Context

StockSavvy.ai notes that Inhibrx Biosciences is operating in the highly competitive and capital-intensive biopharmaceutical sector, with a focus on oncology. The company's progress in clinical trials and regulatory submissions for its novel biologic candidates, ozekibart and ordastobart, aligns with industry trends of developing targeted therapies and combination treatments. The significant investment in R&D and the reliance on external financing are typical for companies at this stage of development.

Comparison to Industry Standards

• Ozekibart's ORR of 20% in colorectal cancer, while an improvement over the 1-6% standard of care, is still a moderate response rate in a highly competitive indication.
• The 52% reduction in PFS risk for ozekibart in chondrosarcoma is a notable achievement, especially given the lack of approved systemic options for this rare cancer, positioning it favorably against historical benchmarks for this specific indication.
• Ordastobart's cORR of 48.3% in HNSCC with pembrolizumab is competitive with other PD-1 inhibitor combinations in this setting, particularly the strong signal in HPV+ patients.
• The company's cash burn rate and need for future financing are consistent with industry norms for clinical-stage biopharmaceutical companies, which often require substantial capital infusions to advance drug candidates through development and regulatory approval.

Legal Proceedings

• The Company is not party to any material legal proceedings.

Stakeholder Impact

• Shareholders may experience dilution if the company raises additional capital through equity offerings.
• Creditors may be subject to covenants limiting the company's actions if debt financing is pursued.
• Employees may be impacted by potential reductions in spending or program eliminations if adequate funding is not secured.
• Suppliers may face extended payment terms if the company faces liquidity constraints.

Next Steps

• Announce interim results from two additional Phase 1 cohorts for ozekibart in CRC during the first quarter of 2027.
• Provide an update on the Ewing sarcoma trial data at the CTOS annual conference in November 2026.
• Evaluate the submission of clinical data to the NCCN for ozekibart inclusion in NCCN Guidelines for Ewing sarcoma.
• Align with the FDA on the regulatory framework for ordastobart and initiate the Phase 3 portion of the HexAgon trial around mid-2027.
• Initiate exploration of ordastobart in combination with therapeutic cancer vaccines.
• Provide initial results from the Phase 1/2 study of ordastobart in the perioperative setting of NSCLC by mid-2027.

Key Dates

Recommendation

The company shows promising clinical data for its lead candidates, ozekibart and ordastobart, with regulatory milestones achieved for ozekibart. However, the significant accumulated deficit, ongoing high R&D expenses, and substantial debt financing with increasing interest expenses, coupled with the reliance on future capital raises, present considerable risks. While the clinical progress is encouraging, the path to profitability is long and uncertain, warranting a 'hold' position until further de-risking events, such as regulatory approvals and successful commercialization, occur.

Keywords

biopharmaceutical, oncology, clinical trials, drug development, ozekibart, ordastobart, FDA, BLA